DOCSLIB.ORG

Calbiochem Inhibitor Sourcebook

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Calbiochem Inhibitor Sourcebook Calbiochem Inhibitor SourceBook Inhibitor SourceBook™ Your #1 Resource for Quality Inhibitors Calbiochem Inhibitor SourceBook Includes inhibitors of • Phosphorylation/ Dephosphorylation For more information or to order Calbiochem products, contact • Apoptosis Merck Biosciences GmbH • Cell Division/Cell Cycle/ Postfach 1167, 65796 Bad Soden Cell Adhesion Germany • Lipid Signaling Orders: Tel 0800 6931 000 • Neurobiology/ Fax 0800 6236 100 Neurodegeneration Technical Support: Tel 0800 100 3496 • Nitric Oxide/ E-mail [email protected] Oxidative Stress Republic of Ireland • Proteases and more ... Tel 1800 409445 Visit our website: www.merckbiosciences.de You can also order Calbiochem products through CB0721 — 2004EUR our distribution partner, VWR International. Tel 0180 570 2000 Web www.vwr.com Calbiochem, Novabiochem, and Novagen are brands of Merck Biosciences, an affiliate of Merck KGaA, Darmstadt, Germany. Printed in the USA. ® PHOSPHORYLATION RESEARCH Calbiochem Novagen® Hundreds of MAPK products. Thousands of citations. Decades of experience. Great reasons to trust Calbiochem brand products for your MAP Kinase research. Also check out: Proteinlounge.com 2004 © Phospho-specific Antibodies PhosphoSafe™ Extraction Buffer and our other phosphorylation research products. www.calbiochem.com/MAPK Leading the way in MAP Kinase Research Contents Phosphorylation/Dephosphorylation . .3 Akt (Protein Kinase B) Inhibitors . .3 Calmodulin-Dependent Protein Kinase (CaM Kinase) Inhibitors . .4 Casein Kinase (CK) Inhibitors . .6 Cyclin-Dependent Kinase (Cdk) Inhibitors . .7 DNA-Dependent Protein Kinase (DNA-PK) Inhibitors . .10 Glycogen Synthase Kinase (GSK) Inhibitors . 11 c-Jun N-Terminal Kinase (JNK/SAP Kinase) Inhibitors . .12 Mitogen-Activated Protein (MAP) Kinase Inhibitors . .13 Myosin Light Chain Kinase (MLCK) Inhibitors . .16 Phosphatidylinositol 3-Kinase (PI 3-Kinase) Inhibitors . .17 Protein Kinase A (PKA; cAMP-Dependent Protein Kinase) Inhibitors . .18 Protein Kinase C (PKC) Inhibitors . .20 Protein Kinase G (PKG; cGMP-Dependent Protein Kinase) Inhibitors . .25 Protein Tyrosine Kinase (PTK) Inhibitors . .27 Raf Kinase Inhibitors . .33 Rho Kinase (ROCK) Inhibitors . .34 Sphingosine Kinase Inhibitors . .34 Protein Phosphatase Inhibitors . .35 Apoptosis . .38 Caspase Inhibitors . .38 Granzyme Inhibitors . .40 Other Inhibitors of Apoptosis . .42 Cell Division/Cell Cycle/Cell Adhesion . .43 Cell Adhesion Inhibitors . .43 DNA Methyltransferase Inhibitors . .45 DNA and RNA Polymerase Inhibitors . .46 Histone Acetylase and Deacetylase Inhibitors . .47 Nuclear Import/Export Inhibitors . .49 Poly(ADP-ribose) Polymerase (PARP) and Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors . .50 Telomerase Inhibitors . .52 Topoisomerase Inhibitors . .54 Lipid Signaling . .56 Cyclooxygenase (COX) Inhibitors . .56 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors . .59 Lipoxygenase (LOX) Inhibitors . .60 Phospholipase Inhibitors . .61 Sphingomyelinase Inhibitors . .63 Calbiochem • Inhibitor SourceBook Technical support [email protected] 1 Visit our website www.calbiochem.com Neurobiology/Neurodegeneration . .64 Amyloidogenesis Inhibitors . .64 Cholinesterase Inhibitors . .65 Monoamine Oxidase (MAO) Inhibitors . .66 Secretase Inhibitors . .67 Nitric Oxide/Oxidative Stress . .70 Arginase Inhibitors . .70 Glutathione S-Transferase (GST) Inhibitors . .70 Guanylate Cyclase (GC) Inhibitors . .71 Nitric Oxide Synthase (iNOS, bNOS, eNOS) Inhibitors . .72 Proteases . .76 Calpain Inhibitors . .76 Collagenase Inhibitors (Also see Matrix Metalloproteinase Inhibitors) . .78 Elastase Inhibitors . .78 Matrix Metalloproteinase (MMP) Inhibitors . .79 Tissue Inhibitors of Matrix Metalloproteinases (TIMPs) . .81 Protease Inhibitors . ..
Load more

Recommended publications
  • (Apis Mellifera) ELISABETH P
    J. Insect Ph.vsiol. Vol. 42, No. 9, pp. 823-828, 1996 Pergamon Copyright 0 1996 Elsevier Science Ltd Printed in Great Britain. All rights reserved PII: SOO22-1910(96)00045-5 0022-1910196 $15.00 + 0.00 Effects of Two Proteinase Inhibitors on the Digestive Enzymes and Survival of Honey Bees (Apis mellifera) ELISABETH P. J. BURGESS,*1 LOUISE A. MALONE,* JOHN T. CHRlSTELLERt Received I1 December 1995; revised und accepted 1 March 1996 Two endopeptidase inhibitors, BPTI (bovine pancreatic trypsin inhibitor) and SBTI (Kunitz soybean trypsin inhibitor), were found to significantly reduce the longevity of adult honey bees (&is mellifera L.) fed the inhibitors ad lib in sugar syrup at l.O%, 0.5% or O.l%, but not at 0.01% or 0.001% (w:v). Bees were taken from frames at emergence, kept in cages at 33”C, and provided with a pollen/protein diet, water and syrup. In vivo activity levels of three midgut endopeptidases (trypsin, chymotrypsin and elastase) and the exopeptidase leucine aminopeptidase (LAP) were determined in bees fed either BPTI or SBTI at l.O%, 0.3% or 0.1% (w:v) at two time points: the 8th day after emergence and when 75% of bees had died. LAP activity levels increased significantly in bees fed with either inhibitor at all concen- trations. At day 8, bees fed BPTI at all concentrations had significantly reduced levels of trypsin, chymotrypsin and elastase. At the time of 75% mortality, bees fed BPTI at each concentration had reduced trypsin levels, but only those fed the inhibitor at the highest dose level had reduced chymotrypsin or elastase activity.
    [Show full text]
  • ATP-Induced Focal Adhesion Kinase Activity Is Negatively Modulated by Phospholipase D2 in PC12 Cells
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 33, No. 3, 150-155, September 2001 ATP-induced focal adhesion kinase activity is negatively modulated by phospholipase D2 in PC12 cells Yoe-Sik Bae1 and Sung Ho Ryu1,2 Introduction 1 Division of Molecular and Life Sciences, Pohang University of Purinergic receptors have been reported to play impor- Science and Technology, Pohang 790-784, Korea tant roles on the regulation of neuronal cell functions 2 Corresponding author: Tel, +82-54-279-2292; (Communi et al., 2000; Di Iorio et al., 1998). ATP, a Fax, +82-54-279-2199; E-mail, [email protected] ligand for the receptors modulate various cellular re- sponses such as mitogenic and morphogenic activity in Accepted 18 September 2001 PC12 rat pheochromocytoma cells (Neary et al., 1996; Soltoff et al., 1998; Schindelholz et al., 2000). Stimu- Abbreviations: Fak, focal adhesion kinase; PLD, phospholipase D; lation of cells with ATP induces tyrosine phosphorylation PA, phosphatidic acid; PC, phosphatidylcholine; DAG, diacylglyc- of several cytoskeletal proteins and focal adhesion erol; PBt, phosphatidylbutanol; PKC, protein kinase C; PAP, phos- molecules such as focal adhesion kinase (Fak), proline- phatidic acid phosphohydrolase rich tyrosine kinase (Pyk2), and paxillin (Soltoff et al., 1998; Schindelholz et al., 2000). Since these cytosk- eleton-associated proteins have been regarded as important factors for the regulation of neuronal cell Abstract functions, the study on the regulatory mechanism for the proteins remains an important issue. Extracellular ATP has been known to modulate vari- Phospholipase D (PLD) catalyzes the hydrolysis of ous cellular responses including mitogenesis, secre- phosphatidylcholine (PC) into phosphatidic acid (PA) tion and morphogenic activity in neuronal cells.
    [Show full text]
  • Datasheet for Protein Phosphatase 1 (PP1) (P0754; Lot 0121306)
    Supplied in: 200 mM NaCl, 50 mM HEPES Unit Definition: One unit is defined as Notes On Use: Avoid freeze/thaw cycles. Can be Protein the amount of enzyme that hydrolyzes 1 nmol of stored for 1 week or less at –20°C. (pH 7.0 @ 25°C), 1 mM MnCl2, 0.1 mM EGTA, Phosphatase 1 2.5 mM dithiothreitol, 0.025% Tween-20 and p-Nitrophenyl Phosphate (50 mM) (NEB #P0757) 50% glycerol. Store at –70°C in 1 minute at 30°C in a total reaction volume of The following information can be used as (PP1) 50 µl. suggested initial conditions for dephosphorylation 1-800-632-7799 Applications: PP1 can be used to release of proteins with PP1. [email protected] phosphate groups from phosphorylated serine, Specific Activity: ~ 80,000 units/mg. www.neb.com 0.1 unit of PP1 removes ~100% of phosphates P0754S 012130614061 threonine and tyrosine residues in proteins. Note that different proteins are dephosphorylated at Molecular Weight: 37.5 kDa. (0.5 nmol) from phosphoserine/threonine different rates. residues in phosphorylase a as well as in P0754S r y Purity: PP1 has been purified to > 90% phosphorylated myelin basic protein (phospho- 100 units 2,500 U/ml Lot: 0121306 Reagents Supplied with Enzyme: homogeneity as determined by SDS-PAGE and MyBP, 18.5 kDa) in 30 minutes in a 50 µl reaction. RECOMBINANT Store at –70°C Exp: 6/14 10X NEBuffer for Protein MetalloPhosphatases Coomassie Blue staining. The concentration of phospho-MyBP is 10 µM (PMP) with respect to phosphate. Description: Protein Phosphatase 1 (PP1) is a 10X MnCl2 (10 mM) Quality Assurance: PP1 contains no detectable Mn2+-dependent protein phosphatase with activity protease activity.
    [Show full text]
  • The Self-Inhibitory Nature of Metabolic Networks and Its Alleviation Through Compartmentalization
    ARTICLE Received 30 Oct 2016 | Accepted 23 May 2017 | Published 10 Jul 2017 DOI: 10.1038/ncomms16018 OPEN The self-inhibitory nature of metabolic networks and its alleviation through compartmentalization Mohammad Tauqeer Alam1,2, Viridiana Olin-Sandoval1,3, Anna Stincone1,w, Markus A. Keller1,4, Aleksej Zelezniak1,5,6, Ben F. Luisi1 & Markus Ralser1,5 Metabolites can inhibit the enzymes that generate them. To explore the general nature of metabolic self-inhibition, we surveyed enzymological data accrued from a century of experimentation and generated a genome-scale enzyme-inhibition network. Enzyme inhibition is often driven by essential metabolites, affects the majority of biochemical processes, and is executed by a structured network whose topological organization is reflecting chemical similarities that exist between metabolites. Most inhibitory interactions are competitive, emerge in the close neighbourhood of the inhibited enzymes, and result from structural similarities between substrate and inhibitors. Structural constraints also explain one-third of allosteric inhibitors, a finding rationalized by crystallographic analysis of allosterically inhibited L-lactate dehydrogenase. Our findings suggest that the primary cause of metabolic enzyme inhibition is not the evolution of regulatory metabolite–enzyme interactions, but a finite structural diversity prevalent within the metabolome. In eukaryotes, compartmentalization minimizes inevitable enzyme inhibition and alleviates constraints that self-inhibition places on metabolism. 1 Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK. 2 Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK. 3 Department of Food Science and Technology, Instituto Nacional de Ciencias Me´dicas y Nutricio´n Salvador Zubira´n, Vasco de Quiroga 15, Tlalpan, 14080 Mexico City, Mexico.
    [Show full text]
  • Chemical Composition and Product Quality Control of Turmeric
    Stephen F. Austin State University SFA ScholarWorks Faculty Publications Agriculture 2011 Chemical composition and product quality control of turmeric (Curcuma longa L.) Shiyou Li Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Wei Yuan Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Guangrui Deng Ping Wang Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Peiying Yang See next page for additional authors Follow this and additional works at: http://scholarworks.sfasu.edu/agriculture_facultypubs Part of the Natural Products Chemistry and Pharmacognosy Commons, and the Pharmaceutical Preparations Commons Tell us how this article helped you. Recommended Citation Li, Shiyou; Yuan, Wei; Deng, Guangrui; Wang, Ping; Yang, Peiying; and Aggarwal, Bharat, "Chemical composition and product quality control of turmeric (Curcuma longa L.)" (2011). Faculty Publications. Paper 1. http://scholarworks.sfasu.edu/agriculture_facultypubs/1 This Article is brought to you for free and open access by the Agriculture at SFA ScholarWorks. It has been accepted for inclusion in Faculty Publications by an authorized administrator of SFA ScholarWorks. For more information, please contact [email protected]. Authors Shiyou Li, Wei Yuan, Guangrui Deng, Ping Wang, Peiying Yang, and Bharat Aggarwal This article is available at SFA ScholarWorks: http://scholarworks.sfasu.edu/agriculture_facultypubs/1 28 Pharmaceutical Crops, 2011, 2, 28-54 Open Access Chemical Composition and Product Quality Control of Turmeric (Curcuma longa L.) ,1 1 1 1 2 3 Shiyou Li* , Wei Yuan , Guangrui Deng , Ping Wang , Peiying Yang and Bharat B. Aggarwal 1National Center for Pharmaceutical Crops, Arthur Temple College of Forestry and Agriculture, Stephen F.
    [Show full text]
  • In Vitro Immunopharmacological Profiling of Ginger (Zingiber Officinale Roscoe)
    Research Collection Doctoral Thesis In vitro immunopharmacological profiling of ginger (Zingiber officinale Roscoe) Author(s): Nievergelt, Andreas Publication Date: 2011 Permanent Link: https://doi.org/10.3929/ethz-a-006717482 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library DISS. ETH Nr. 19591 In Vitro Immunopharmacological Profiling of Ginger (Zingiber officinale Roscoe) ABHANDLUNG zur Erlangung des Titels DOKTOR DER WISSENSCHAFTEN der ETH ZÜRICH vorgelegt von Andreas Nievergelt Eidg. Dipl. Apotheker, ETH Zürich geboren am 18.12.1978 von Schleitheim, SH Angenommen auf Antrag von Prof. Dr. Karl-Heinz Altmann, Referent Prof. Dr. Jürg Gertsch, Korreferent Prof. Dr. Michael Detmar, Korreferent 2011 Table of Contents Summary 6 Zusammenfassung 7 Acknowledgements 8 List of Abbreviations 9 1. Introduction 13 1.1 Ginger (Zingiber officinale) 13 1.1.1 Origin 14 1.1.2 Description 14 1.1.3 Chemical Constituents 15 1.1.4 Traditional and Modern Pharmaceutical Use of Ginger 17 1.1.5 Reported In Vitro Effects 20 1.2 Immune System and Inflammation 23 1.2.1 Innate and Adaptive Immunity 24 1.2.2 Cytokines in Inflammation 25 1.2.3 Pattern Recognition Receptors 29 1.2.4 Toll-Like Receptors 30 1.2.5 Serotonin 1A and 3 Receptors 32 1.2.6 Phospholipases A2 33 1.2.7 MAP Kinases 36 1.2.8 Fighting Inflammation, An Ongoing Task 36 1.2.9 Inflammation Assays Using Whole Blood 38 1.3 Arabinogalactan-Proteins 39 1.3.1 Origin and Biological Function of AGPs 40 1.3.2 Effects on Animals 41 1.3.3 The ‘Immunostimulation’ Theory 42 1/188 2.
    [Show full text]
  • Treatment Protocol Copyright © 2018 Kostoff Et Al
    Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention.
    [Show full text]
  • Plant Protease Inhibitors: a Defense Strategy in Plants
    Biotechnology and Molecular Biology Review Vol. 2 (3), pp. 068-085, August 2007 Available online at http://www.academicjournals.org/BMBR ISSN 1538-2273 © 2007 Academic Journals Standard Review Plant protease inhibitors: a defense strategy in plants Huma Habib and Khalid Majid Fazili* Department of Biotechnology, The University of Kashmir, P/O Naseembagh, Hazratbal, Srinagar -190006, Jammu and Kashmir, India. Accepted 7 July, 2007 Proteases, though essentially indispensable to the maintenance and survival of their host organisms, can be potentially damaging when overexpressed or present in higher concentrations, and their activities need to be correctly regulated. An important means of regulation involves modulation of their activities through interaction with substances, mostly proteins, called protease inhibitors. Some insects and many of the phytopathogenic microorganisms secrete extracellular enzymes and, in particular, enzymes causing proteolytic digestion of proteins, which play important roles in pathogenesis. Plants, however, have also developed mechanisms to fight these pathogenic organisms. One important line of defense that plants have to fight these pathogens is through various inhibitors that act against these proteolytic enzymes. These inhibitors are thus active in endogenous as well as exogenous defense systems. Protease inhibitors active against different mechanistic classes of proteases have been classified into different families on the basis of significant sequence similarities and structural relationships. Specific protease inhibitors are currently being overexpressed in certain transgenic plants to protect them against invaders. The current knowledge about plant protease inhibitors, their structure and their role in plant defense is briefly reviewed. Key words: Proteases, enzymes, protease inhibitors, serpins, cystatins, pathogens, defense. Table of content 1.
    [Show full text]
  • Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
    Published OnlineFirst June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 RESEARCH ARTICLE Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers Timothy A. Yap1,2, Rebecca Kristeleit3, Vasiliki Michalarea1, Stephen J. Pettitt4,5, Joline S.J. Lim1, Suzanne Carreira2, Desamparados Roda1,2, Rowan Miller3, Ruth Riisnaes2, Susana Miranda2, Ines Figueiredo2, Daniel Nava Rodrigues2, Sarah Ward1,2, Ruth Matthews1,2, Mona Parmar1,2, Alison Turner1,2, Nina Tunariu1, Neha Chopra1,4, Heidrun Gevensleben2, Nicholas C. Turner1,4, Ruth Ruddle2, Florence I. Raynaud2, Shaun Decordova2, Karen E. Swales2, Laura Finneran2, Emma Hall2, Paul Rugman6, Justin P.O. Lindemann6, Andrew Foxley6, Christopher J. Lord4,5, Udai Banerji1,2, Ruth Plummer7, Bristi Basu8, Juanita S. Lopez1,2, Yvette Drew7, and Johann S. de Bono1,2 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 ABSTRACT Preclinical studies have demonstrated synergy between PARP and PI3K/AKT path- way inhibitors in BRCA1 and BRCA2 (BRCA1/2)–deficient andBRCA1/2 -proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient dose- escalation design to assess two schedules of capivasertib (AKT inhibitor) with olaparib (PARP inhibi- tor) in 64 patients with advanced solid tumors. Dose expansions enrolled germline BRCA1/2-mutant tumors, or BRCA1/2 wild-type cancers harboring somatic DNA damage response (DDR) or PI3K–AKT pathway alterations. The combination was well tolerated. Recommended phase II doses for the two schedules were: olaparib 300 mg twice a day with either capivasertib 400 mg twice a day 4 days on, 3 days off, or capivasertib 640 mg twice a day 2 days on, 5 days off.
    [Show full text]
  • Effect of Statins and ACE Inhibitors Alone and in Combination on Clinical Outcome in Patients with Coronary Heart Disease
    Journal of Human Hypertension (2004) 18, 781–788 & 2004 Nature Publishing Group All rights reserved 0950-9240/04 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease VG Athyros1, DP Mikhailidis3, AA Papageorgiou2, VI Bouloukos1, AN Pehlivanidis1, AN Symeonidis4 and M Elisaf5, for the GREACE Study Collaborative Group 1Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; 2Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, London, UK; 32nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; 4Greek Society of General Practitioners, Thessaloniki, Greece; 5Department of Internal Medicine, Medical School, University of Ioannina, Greece We assessed the ‘synergy’ of statins and angiotensin- point in group A was 31%, (95% CI À48 to À6%, P ¼ 0.01) converting enzyme inhibitors (ACEI) in reducing vascu- in comparison to group B, 59% (95% CI À72 to À48%, lar events in patients with coronary heart disease (CHD). Po0.0001) to group C and 63% (95% CI À74 to À51%, The GREek Atorvastatin and CHD Evaluation (GREACE) Po0.0001) to group D. There was no significant Study, suggested that aggressive reduction of low difference in RRR between groups C and D (9%, CI density lipoprotein cholesterol to 2.59 mmol/l À27–10%, P ¼ 0.1). Other factors (eg the blood pressure) (o100 mg/dl) significantly reduces morbidity and mor- that can influence clinical outcome did not differ tality in CHD patients, in comparison to undertreated significantly between the four treatment groups.
    [Show full text]
  • Combined Neprilysin and Renin–Angiotensin System Inhibition in Heart Failure with Reduced Ejection Fraction: a Meta-Analysis
    European Journal of Heart Failure (2016) doi:10.1002/ejhf.603 Combined neprilysin and renin–angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis Scott D. Solomon1*, Brian Claggett1, John J.V. McMurray2, Adrian F. Hernandez3, and Gregg C. Fonarow4 1Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2University of Glasgow, Glasgow, UK; 3Duke University, Durham, NC, USA; and 4Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA Received 1 March 2016; revised 25 May 2016; accepted 3 June 2016 Aims The combined neprilysin/renin–angiotensin system (RAS) inhibitor sacubitril/valsartan reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all-cause mortality in a large outcomes trial. While sacubitril/valsartan is the only currently available drug in its class, there are two prior clinical trials in heart failure with omapatrilat, another combined neprilysin/RAS inhibitor. Using all available evidence can inform clinicians and policy-makers. ..................................................................................................................................................................... Methods We performed a meta-analysis using data from three trials in heart failure with reduced EF that compared combined and results neprilysin/RAS inhibition with RAS inhibition alone and reported clinical outcomes: IMPRESS (n = 573), OVERTURE (n = 5770), and PARADIGM-HF (n = 8399). We assessed the pooled hazard ratio (HR) for all-cause death or heart failure hospitalization, and for all-cause mortality in random-effects models, comparing combined neprilysin/RAS inhibition with ACE inhibition alone. The composite outcome of death or heart failure hospitalization was reduced numerically in patients receiving combined neprilysin/RAS inhibition in all three trials, with a pooled HR of 0.86, 95% confidence interval (CI) 0.76–0.97, P = 0.013.
    [Show full text]
  • ISOLATION, CHARACTERISATION AND/OR EVALUATION of PLANT EXTRACTS for ANTICANCER POTENTIAL KARUPPIAH PILLAI MANOHARAN (M.Sc., M.Ph
    ISOLATION, CHARACTERISATION AND/OR EVALUATION OF PLANT EXTRACTS FOR ANTICANCER POTENTIAL KARUPPIAH PILLAI MANOHARAN (M.Sc., M.Phil., B.Ed.,) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF CHEMISTRY NATIONAL UNIVERSITY OF SINGAPORE 2006 Acknowledgements I wish to express my sincere gratitude and appreciation to my supervisors, Associate Prof. Yang Dai Wen and Associate Prof. Tan, Benny Kwong Huat for their advice, suggestions, constructive criticisms, critical comments and constant guidance throughout the course my study. I am very thankful to Asst. Prof. Henry, Mok Yu-Keung; his supervisor-like role throughout my research work is greatly appreciated. I am very grateful to Prof. Sim Keng Yeow for his help, support and guidance at the beginning of this course of study. I would like to thank all the technical staffs of Departments of Chemistry and Pharmacology for their superb technical assistance. My sincere thanks are due to Ms. Annie Hsu for her technical assistance at the traditional medicine and natural product research laboratory, Department of Pharmacology, Faculty of Medicine. I would like to thank Dr. Fan Sing Jong, NMR Manager for his help in the structure elucidation. I would like to thank Associate Prof. Hugh Tan Tiang Wah and Chua Keng Soon, Senior Laboratory Officer (RMBR), Herbarium, for the identification of plant materials, Eugenia grandis and Fagraea fragrans. I am very grateful to the former head Prof. Lee Hian Kee and the present head Prof. Hor Tzi Sum, Andy, Department of Chemistry for facilitating requests and approvals during the period of my study. My appreciation also goes to all my friends.
    [Show full text]